

REVIEW ARTICLE

Iran J Allergy Asthma Immunol
December 2015; 14(6):552-568.

Therapeutic Potential of Mesenchymal Stem Cells for the Treatment of Airway Remodeling in Pulmonary Diseases

Amir Nejad-Moghaddam¹, Yunes Panahi¹, Meghdad Abdollahpour Alitappeh², Hojat Borna¹,
Mohammad Ali Shokrgozar³, and Mostafa Ghanei¹

¹ Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

² Department of Immunology, Pasteur Institute of Iran, Tehran, Iran

³ National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran

Received: 3 December 2014; Received in revised form: 11 January 2015; Accepted: 11 January 2015

ABSTRACT

According to significant improvements in the tissue engineering field over the past several years, lung tissue cells have recently attracted more attention due to the high prevalence and diversity in related diseases.

However, selection of an appropriate cell type, screening of suitable conditions for growth and proliferation, as well as subsequent implantation into the body to repair and regenerate damaged tissues are considered as important issues in this context.

It should also be noted that most studies have been described in animal models, but not in humans. Because of the high regenerative capacity, predominant immunomodulatory feature, and inhibition of T-lymphocyte proliferation, mesenchymal stem cells (MSCs) may play an important role in the reconstruction of damaged tissues including bronchioles in pulmonary diseases.

Interestingly, clinical trial studies demonstrated that MSCs have the significant potential to treat a wide variety of diseases including acute myocardial infarction (AMI), liver cirrhosis, crohn's disease, and graft-versus-host disease (GVHD).

Keywords: Adipose-derived mesenchymal stem cell; Airway remodeling; Chronic bronchitis; Chronic obstructive pulmonary disease; Inflammation; Lung diseases; Mesenchymal stem cell

INTRODUCTION

The respiratory system is one of the most complex organs in the body. Because of its anatomical position and composition after exposed to various damaging

factors such as micro particles, carbon granules, toxic gases (including sulfur dioxide, nitrogen oxides, ozone etc), the respiratory system is prone to a wide variety of irreversible damages and alterations.¹⁻³ Both acute and chronic lung injuries include a variety of symptoms, ranging from mild and reversible such as allergies to severe and irreversible problems such as fibrosis, fatal asthma and chronic obstructive diseases. In most diseases involving the airways, the epithelial linings of

Corresponding Author: Mostafa Ghanei, MD,
Chemical Injuries Research Center, Baqiyatallah University of
Medical Sciences, Mollasadra Street, 19945-546, Tehran, Iran. Tel:
(+98 21)8860 0067; E-mail: m.ghanei@bmsu.ac.ir

Mesenchymal Stem Cell Therapy for Pulmonary Diseases

the airway are found to be at risk of irreversible damages that cannot naturally be repaired. However, the standard treatment approaches involve surgery and lung transplantation. The prolonged use of bronchodilators can be helpful, if the terminal airways or bronchioles are damaged. However, long-term bronchodilator therapy can lead to major problems and safety concerns in the patients.⁴ Therefore there is a need for a new therapeutic strategy to overcome these problems.

In recent years, significant advances have been made in the ability of stem cells to treat various diseases. Similar to most tissues, the pulmonary system contains stem cells such as ductal cells, basal cells (BCs), clara cells and alveolar type II cells in the primary bronchi, terminal bronchioles, bronchioles and alveolar regions, respectively.^{5,6} Although lung stem cells have the ability to repair and reconstruct lung tissue, this decreases with age and severity of damage.⁶⁻⁸ However, a number of recent studies indicated that embryonic and mesenchymal stem cells (MSCs) derived from bone marrow are able to convert into airway and epithelial cells in the lung.^{9,10}

Based on these studies, it is proposed that the use of stem cells from other sources such as mesenchymal stem cells may provide a logical solution. Although embryonic stem cells have a high proliferation and differentiation capacity, the risks of tumorigenesis and transplantation rejection as well as ethical issues make the clinical application of these cells challenging.¹¹ Due to the high regenerative potential, along with the immunomodulatory features and inhibition of T-lymphocyte proliferation, the MSCs may play important roles in the reconstruction of damaged tissues.⁵ Further experiments demonstrated that the intravenous injection of MSCs increases their localization in the alveolar spaces and airways.^{12,13} Nonetheless, one of the most important challenges for the use of MSCs in lung lesions is the low level of cell engraftment in damaged lung tissue.¹³

As progenitor cells of the connective-tissue or multipotent mesenchymal stromal cells, MSCs have been shown to have the therapeutic potential for lung injury.¹⁴ MSCs can be isolated from different adult tissues and differentiated into various cell types. Several studies showed that MSCs mediate beneficial effects in the repair of damaged tissues. After in vitro culture, growth and proliferation, MSC engraftment in damaged tissue may induce moderate inflammatory responses by pro-inflammatory cytokines. In addition,

MSCs lead to a significant immune suppression that can modulate the function and activity of T lymphocyte cells (T cells), Natural killer (NK) cells, and dendritic cells (DCs). Preclinical studies also demonstrated that the use of MSCs in clinical trials can be highly valuable.¹⁵ The clinical properties of MSCs are as follows:¹⁶⁻²⁰

1. MSCs can be easily isolated from bone marrow and adipose tissue.
2. Intravenously injected cultured MSCs have the ability of localization without toxicity to the host.
3. MSCs have the potential to differentiate into specific cell types in tissues, with immunosuppressive effects.
4. MSCs are not immunogenic; in other words, engraftment is not associated with rejection, and no immunosuppressive therapy is needed.
5. There are no ethical issues pertaining to the therapeutic use of MSCs.

The data from clinical trials showed that MSCs are the most effective for the treatment of diseases such as acute myocardial infarction (AMI),²¹ liver cirrhosis,²² crohn's disease²³ and graft-versus-host disease (GVHD)²⁴ in phase III clinical trials, and Type 1 diabetes,²⁵ arthritis²⁶ and lung diseases such as COPD²⁷ in phase II clinical trials.

In this review, we will address both the MSC-associated studies in animal models and MSC-based therapeutic strategies as well as pulmonary diseases.

Stem Cell Dynamics in the Lung Epithelial Cell Layers

The lung tissue, both the proximal and distal airways, contains a wide variety of structurally and functionally distinct epithelial cell types that can also be found in other locations. The bronchial region (large airways) often includes ciliated, mucus-secreting cells, and BCs. Bronchioles (small airways) contain Clara cells as well as alveolar type I and type II cells (Figure 1).²⁸ Several potential sources of stem cells were so far identified for repairing the airway epithelial layer. They can be classified into endogenous progenitor cells in the respiratory tract, and exogenous stem cells derived from other tissues of the body. Studies showed that secretory and basal cell types are parts of the airway epithelial stem cells, accounting for up to 6-30% of the airway epithelia involved in normal homeostasis and regeneration of injured tissue.²⁸⁻³⁰ Several studies demonstrated that dynamic airway epithelial repair includes de-differentiation, cytoskeleton




Figure 1. A schematic diagram depicting various parts of progenitor stem cells in the airway. As the progenitor epithelial cells, Clara cells and BCs reside in airways and alveolar type II cells do in the alveolar region.

rearrangement, migration and re-differentiation, respectively.³¹⁻³³

Airway epithelial damage can result from a number of unknown airway diseases, toxins, bacterial or viral infections, allergic reactions, exposures to tobacco smoke and chemical agents (such as chemical compositions of fine particles suspended in the air, or active compounds from industrial and military agents), physical damages and cancers.^{34,36} Although the cells of airway walls are able to regenerate and restore their normal structure under normal conditions, if the damage is severe enough, the repair process will be further impaired, leading to more extensive damage that is more difficult to repair, called airway remodeling.³⁷⁻³⁹ Airway remodeling includes changes in the epithelial structures such as subepithelial fibrosis, increased mass of smooth muscles, enlargement of mucous glands and angiogenesis (Figure 2).^{40,41} TGF- β that is a factor produced by epithelial cells and fibroblasts, plays an important role in rearrangement of airways in chronic lung disease.⁴²⁻⁴⁴ In addition, TGF- β was found to increase the expression of extracellular matrix components such as collagen. On the other hand, TGF- β decreases the expression of matrix metalloproteinases (MMPs), and increases the expression of tissue inhibitor of matrix metalloproteinases (TIMPs), resulting in the collagen

accumulation and fibrosis formation.⁴⁵⁻⁴⁷ In response to the chronic injuries, remodeling includes decreased airflow, airway obstruction and high sensitivity.⁴⁸

In many airway diseases including asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), small airways, especially epithelium, are damaged, exhibiting a marked delay in repair.⁴⁹⁻⁵² Because of the low half-life of ciliated cells in the trachea and lungs, the ability to renew and repair the epithelial layer is considered to be slow.⁶

Following injury, the repair process initiated in the airway epithelia includes acute inflammatory responses, recruitment of immune cells (such as neutrophils and macrophages), migration and proliferation of epithelial progenitor cells. Additionally, factors such as epithelial and fibroblast growth factors, chemokines and interleukins [Interleukin-1 β (IL-1 β), -2, -4 and -13] as well as prostaglandins (such as PGE2) are released during the lung injury.³⁴⁻³⁶ It should be noted that although injury can occur in the distal and proximal airways, the initiation of injury in epithelial cells is similar to that of different sources. Progenitor cells migrate and the epithelial-free surfaces are lined by a layer of epithelial cells.³⁵

Clara cells, known as progenitor cells of the bronchial epithelium,^{47,53} seem to play an important functional role of stem cells in airways.⁶




Figure 2. Damage stages of the airway epithelial layer and incomplete repair processes after injury.

During lung injury, ciliated cells damaged by chemical gas may be replaced by Clara cells starting to proliferate.⁵⁴ When the intact mouse is exposed to chemical agents such as bleomycin, more Clara cells die due to toxic metabolic activities. Ciliated cells are shed, leaving the bronchial basal membrane naked. Subsequently, only a few Clara cells survive and begin to proliferate. Bleomycin-resistant progenitor cells, a set of Clara cells residing within neuroepithelial bodies, are able to generate a mass of stem cells.⁵⁵ The Second epithelial stem cell population found in an area of distal airways is called alveolar type II cells which include 16% of the total alveolar cells. Seven percent of the alveolar surface was covered with alveolar type II cells, expressing high levels of the surfactant protein C.⁵⁶

Molecular mechanisms governing the generation and separation of such cell types in the airways are not well understood. However, it has been found that airway progenitor cells fail to generate epithelial cells under severe injury conditions. In addition, mucus-producing cells are most active after injury in the lungs; this is more common in patients with severe asthma. The presence of inflammatory cytokines, such as IL-9, IL-10 and IL-13, is involved in difficulty breathing and chest tightness.⁵⁷⁻⁵⁹

Characteristics and Homing of MSCs

There are complex sets of non-hematopoietic cells

in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells.^{60,61} MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition.^{62,63} According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers (Table 1).^{14,64,65}

Table 1. List of MSCs surface markers in cell culture

Surface markers	Expression (+) or No expression (-)
CD29	+
CD31	-
CD34	-
CD44	+
CD45	-
CD73	+
CD90	+
CD105	+
HLA-DR	-
HLA-ABC	+

In addition, they have the ability to generate differentiated tissues such as bone, cartilage, adipose, astrocyte, tenocyte and myocyte in in-vitro conditions (Figure 3).⁶⁶⁻⁶⁸ MSCs can also differentiate into ectodermal and endodermal cells.⁶⁹ It has been shown that adipose-derived MSCs are able to differentiate not only into the primary muscle cells, but also into the skeletal and smooth muscle cells, following as an appropriate stimulation.⁷⁰⁻⁷² There is a variety of potential advantages supporting the application of MSCs in cell therapy, such as plasticity properties, ease cultural, easy isolation from bone marrow or other tissues, immunomodulatory function and lack of ethical considerations.⁷³⁻⁷⁵

The process of MSC homing is initiated by cell migration into vascular endothelium, followed by MSC localization within the tissue. However, the data revealed that localization and homing of MSCs are very infrequent after the infusion. There are several factors that play critical roles in the MSC homing.^{76,77} It is supposed that the migration of MSCs is directed by a concentration gradient of the chemokines. Elevated levels of inflammatory chemokines are the key mediator for trafficking of MSCs to the site of injury. Chemokines are released after tissue damage, and induce MSCs to express several receptors for the chemokines.^{78,79} The interaction of MSCs with chemokine gradients is an important step in the activation of MSC mobilization towards the site of injury (Figure 4).⁸⁰

During multiple passages in vitro, MSCs exhibit a

series of surface receptors with increased or decreased expression profiles, such as CXCR3, CXCR4, CXCR6, CCR9 and CCR10, which might involve homing ability. CXCR4 is an SDF-1 receptor displaying increased expression in bone marrow stem cells, damaged tissue and tumor cells, while not usually expressed on the MSC surfaces in continuous cultures.⁸¹ The interaction of SDF-1 α , also termed CXCL12, with the CXCR4 receptor enhances the MSC activation, survival, proliferation and migration to the site of injury. The SDF-1 α chemotactic factor produced at the site of injury leads to the recruitment and activation of MSCs for repairing the damaged tissue. However, when damage is severe enough, healing is not completed.⁸²⁻⁸⁴ In response to SDF-1, MSCs express several adhesion molecules as well as chemokines such as CXCL16, CCL21 and CCL19.⁸⁵⁻⁸⁷ SDF-1/CXCR4 is responsible for both cell cycle arrest and inhibition of homing the CXCR4-expressing cells to the site of injury.⁸⁸

During the homing process, different mechanisms are involved in MSC trafficking, which is performed very slowly within the bloodstream. Large size of MSCs or thin capillaries can reduce their speed due to the physical interactions. In small veins, MSCs display the leukocyte-like processes (Tethering and Rolling) using p-selectin and VLA-4/VCAM-1.

MSCs anchor vascular epithelial cells, diffuse across vascular membranes and reach the site of injury in the epithelial layer through ECM⁸⁹⁻⁹¹ (Figure 4).




Figure 3. The ability of MSCs to self-renew and differentiate into various tissues such as bone, cartilage, adipose etc.

Mesenchymal Stem Cell Therapy for Pulmonary Diseases




Figure 4. Steps of localization and homing of MSC in lung tissue and recruitment with chemokine gradient concentration.

Molecules Secreted by MSCs

MSCs secrete large molecules such as growth factors, chemokines, cytokines and hormones that not only play different roles in cellular functions, but also have paracrine effects on immune cells and their migration to target sites of injury.⁹²

MSCs secrete various biological factors either with proliferating or with anti-inflammatory effects, including Interleukin-37 (IL-37), transforming growth factor- β 1 (TGF- β 1), vascular endothelial growth factor (VEGF), prostaglandin-E2 (PGE-2), hepatocyte growth factor (HGF), nitric oxide (NO) and hemeoxygenase-1 (HO-1). These factors secreted by MSCs can exert an immunosuppressive effect through the inhibition of T-cell proliferation and induction of Treg cell proliferation.^{66,93}

MSCs inhibit DC, T helper cell and NK cell function through the inhibition of pro-inflammatory cytokine secretion such as interferon-gamma (IFN- γ), IL-1 β and tumor necrosis factor (TNF- α), whereas inducing increased expression of anti-inflammatory cytokines such as IL-10.⁹⁴ IL-10 prevents the apoptosis, and decreases the reproduction and activation of lymphocytes.^{12,95}

The Immunomodulatory Properties of MSCs

MSCs are able to modify immune responses including cell proliferation and cytokine production, as well as inhibit cytotoxicity of T cells and NK cells. In chronic inflammatory diseases, studies have shown that

MSCs can reduce innate immune responses and may surprisingly have the ability to change adaptive immune responses through their impact on T-cells. In this regard, there are a number of cell surface and intracellular molecules that elicit a strong immune response or induced immune suppression. Adhesion molecules and major histocompatibility complex (MHC) antigens play a key role in the interaction with immune cells, co-stimulatory molecules and ligand-Fas receptors, which are essential for the activation of T cells.^{106,107} MSCs induce the immune tolerance not only through a reduction in some surface antigens like MHC class I and II, and co-stimulatory molecules such as B7-2 and B7-1, but also through an increase in the expression of some co-inhibitory molecules like B7-H1 and B7-H4.^{108,109} In contrast to the other adhesion molecules, ICAM1 is only expressed under induction conditions. MSCs also express Toll like receptors (TLRs), indicating their immunomodulatory properties.^{110,111} Studies have demonstrated that MSCs are able to alter cell proliferation, migration, differentiation and immunosuppressive potentials of other immune system cells by activation of TLR ligands on their surface.^{112,113} In addition to differentiation potentials, MSCs display immune regulatory activities like inhibition of various innate and adaptive immune cells, including antigen-presenting cells (APCs), B cells, macrophages, DCs, NK cells, CD8+ cytotoxic T lymphocytes (CTL) and regulatory T cells (Tregs). Some of these complex




Figure 5. The interaction between MSCs and different cell types involved in both innate and cellular immunity. The release of secreted factors from MSCs leads to a decrease in the proliferation of T and B lymphocytes, NK cells and DCs, as well as an increase in the induction of Treg cells.

mechanisms are not yet clearly understood (Figure 5).¹¹⁴⁻¹¹⁸

The Crosstalk Between MSCs and Immune cells

It is clearly demonstrated that MSCs inhibit T cell proliferation in cell culture conditions.¹¹⁹ In fact, the expression of some surface markers in lymphocytes decreases in the presence of MSCs. As a result, MSCs are usually used to inhibit CD8⁺ and CD4⁺ T cells.¹²⁰ In the presence of MSCs, T-cell proliferation is suppressed at G0 phase of cell cycle.⁹³

MSCs modulate the immune responses and lymphocyte proliferation through the induction of Tregs by two ways including cell-to-cell contact between MSCs and T CD4⁺ cells and also secretion of PGE-2 and TGF-β1.¹¹⁵

MSCs are able to generate Treg cells through differentiation induction of CD4⁺ T cells into Th1 and Th17 pro-inflammatory cells.¹²¹ Several studies indicated that there are beneficial effects of MSC injection along with Th17 suspension into a mouse model of autoimmune diseases. The increased levels of

lymphocytes such as CD4⁺ CD25⁺ Foxp3⁺ cells are reported in the early stages of the disease.¹²¹ Inhibition of co-stimulatory molecules such as HLA-G by specific blocking antibodies leads to increased T lymphocyte proliferation, suggesting that these molecules are involved in the immune suppression function.^{122,123}

Due to PGE-2, IDO and HGF secretion, MSCs inhibit both B-cell proliferation and antibody production.^{114,124} MSCs inhibit IL-2-induced proliferation of NK cells via immunosuppressive factors such as TGF-β and PGE-2.^{115,125} MSCs also inhibit effective functions of NK cells, such as cytotoxicity against virus-infected cells with a reduction of IFN-γ secretion.²¹

DCs play an important role in survival and regulation of immune responses through the activation of antigen-specific T cells and stimulation of innate immune system cells.^{126,127} Recent studies represented impacts of MSCs on the function of DCs. In contrast to their effect on effector immune cells, MSCs have the ability to mediate a low expression of stimulatory molecules on DCs, thus preventing differentiation of

monocytes into mature DCs.¹²⁸

Consistent with this interpretation, a lot of reports have shown that MSCs establish an immunosuppressive microenvironment through the induction of pro-inflammatory T cells that have a regulatory phenotype. These results may provide a chance for MSC utilization in the treatment of inflammatory and autoimmune diseases.¹²¹

Functional Evaluation of MSCs in Animal Airway Treatment

Several methods are used to evaluate MSC function in animal models. Stem cells are able to localize at the site of injury, proliferate and reproduce airway epithelial cells. To achieve this features, many researchers have developed mouse models with airway diseases to investigate the repair process using different approaches of MSCs administration .

In a mouse model of E.coli endotoxin-induced acute lung injury, the concentration of the KGF molecule on alveolar fluid was evaluated during two stages (before and after the application of human MSCs). The high levels of a KGF factor are found during the administration of MSCs, demonstrating MSC migration at the site of lung injury. Since secretion of considerable amounts of KGF by MSCs is required for MSC renewal. KGF can be also used as a marker for assessing MSC function in the site of injury.¹⁰⁵

Protein and cytokine profiles in Bronchoalveolar lavage (BAL) fluid, such as macrophage inflammatory protein 2 (MIP-2), which is a murine neutrophil chemokine, can be measured by ELISA. However, protein concentration in BAL fluid can be consider as a marker for lung epithelial and endothelial permeability.¹²⁹

Using lung protein sample, SDS-page and western blotting analyses, it is possible to monitor the presence of vascular cell adhesion molecule 1 (VCAM-1), cytochrom C (Cyt C), intercellular adhesion molecule 1 (ICAM-1) and TNF- α . In addition to the above-mentioned approach, analysis of inflammatory gene expression (mRNA), apoptosis and oxidative stress in the damaged lung parenchyma can also provide suitable diagnostic tests for Adipose-Derived MSCs (ADMSC) functions of the lung. According to this interpretation, mRNA expression of three inflammatory markers, IL-1b, TNF-a and MMP9, should be increased, in comparison to anti-inflammatory markers, endothelial nitric oxide synthase (eNOS), IL-10 and

adiponectin. Furthermore, mRNA expression of three antioxidant indicators, hemeoxygenase (HO) -1, glutathione reductase (GR) and glutathione peroxidase (GPx), might be decreased in patient groups. These findings indicated that administration of ADMSC can induce increased antioxidant effects .¹³⁰

Jianguo et al. studied C57BL/6-Tg mice with bleomycin-induced lung injury that expressed high levels of GFP in all their cells. Following injection of MSCs, the lungs of mice were processed and stained with hematoxylin and eosin (H&E) for histopathological studies. The histopathological findings were analyzed to detect inflammatory mediators such as INF- γ , IL-1b, MIP-1a, IL-8 and IL-12 and to evaluate the morphological and functional characteristics of the inflammatory cell.¹³¹

BCs, normally residing in the lung and tracheal airway epithelium of both mice and human beings, are believed to be stem cells. The activation of BCs and Nichs is regulated through a series of signals (mp7, jagged2, Wnt3a etc), receptors (Ngfr, Ptch2, Egfr etc) and antagonists of intracellular signaling pathways (Socs3, sprouty1, Sfrp1etc), all of which can be used as diagnostic markers to determine the BC function.¹³²

Clara cells express specific factors such as Clara cell secretory protein (CCSP), which can be readily analyzed through examining RNA levels before and after cell therapies.³² In a study performed by Loi et al. (2007), bone marrow cells of male mice were used in a female mouse model of cystic fibrosis. The cells concentrated in the lung and differentiated into epithelial cells were evaluated via the FISH technique for Y chromosome.¹³³ The results demonstrated that a small number of bone marrow cells can home in the target tissue. During the homing process, the increased expression of surface markers CD34 and SCA-1 was found on the bone marrow cells.¹³⁴

In another experiment, cells from a female mouse with a lacZ/neomycin resistance gene cassette were used as donors. LacZ expression was detected by X-gal staining in the recipient mouse.¹³⁵ After administration of MSCs, a mouse model of airway injury exhibited the decreased and increased expression levels of TGF- β and IL-10, respectively.¹³² However, one of the most important points to be noted here is differences between the human and mouse models. Detection of cell therapy problems after injection in proximal (bronchus) and distal (alveolar) airways is the main concern in this type of research.

The Role of MSCs in Treatment of Toxic- and Chemical-induced Lung Injuries

Over the past decade, a number of studies have shown that MSCs display great plasticity and are able to differentiate into bronchial epithelium, alveolar, vascular epithelium and different interstitial cells.¹³⁶ In addition, several studies indicated that the conversion of the cells in the normal lungs is relatively low.¹³⁷⁻¹³⁹ In the normal lung, adult stem cells reside in specific areas called niches to maintain homeostasis of the lung tissue. Further knowledge on the characteristics and dynamics of cell lineages in the airway, alveolar epithelial and cell sections of lung MSCs are important principles for the treatment of airway remodeling.

Clinical Trials

In 2012, a group of US researchers investigated the potential efficacy of MSC administration for the treatment of airway diseases, which is currently being investigated in a phase II clinical trial. In that study, it was shown that after 2 years of follow-up post MSC administration, no improvement was observed in the patients with moderated symptoms. However, the overall purpose of the project was to determine the safety and efficacy of MSCs.¹⁴⁰ In the studies by Jeong Chan et al., the safety of human Adipose Tissue-Derived Mesenchymal Stem Cells (hATDMSC) for the treatment of toxicity and tumorigenesis have been demonstrated in animals and human subjects.¹⁴¹

In another study in 2013, Angelini et al. examined the possibility to use stem cells in the treatment of lung diseases caused by different chemical warfare agents and biological toxins. In their study, it was revealed that damaging elements can lead to the acute lung injury and respiratory distress syndrome. The researchers suggested that the different stem cells, particularly MSCs, can be used for the treatment of patients.¹⁴²

In light of this, a study was performed by Liang et al. in 2012 for the treatment of bronchiolitis obliterans syndrome (BOS). It was found that intravenous injection of bone marrow-derived MSCs facilitates more rapid repair in patients, without side effects; pulmonary function tests and Spirometric measurements were analyzed to evaluate their potential role for the treatment of patients.¹⁴³

In 2007, Vladimir et al. showed that bone marrow-derived MSCs are able to engraft in a small and large airway injury from 2 to 6 days after lung damage.¹⁴⁴

Gomperts et al. in 2007 also demonstrated the effects of keratinocyte growth factor to repair epithelial tissues in bronchial ducts. The study showed that keratinocyte growth factor can stimulate the migration of epithelial progenitor cells from the bone marrow into blood circulation and subsequently into the sites of injury.¹⁴⁵

In a clinical trial by Tzouveleakis et al., adipose-derived mesenchymal stem cells were used for the treatment of idiopathic pulmonary fibrosis. Preliminary results showed that no allergic reactions, infections, acute exacerbations or ectopic tissue formations have been attributed to the stem cells. In addition, based on 6-months follow-up data there were no significant differences in the 6 min walk test (6MWT) and forced vital capacity (FVC).¹⁴⁶

In a study by Nichols et al. in 2012, histologically normal lung tissues were used to construct a three-dimensional scaffold for lung tissue engineering. These scaffolds have a high potential to support the cell proliferation in the lung tissue and can have many applications in lung tissue repair.¹⁴⁷

Animal Models and ex vivo Studies

In a study in 2007, Gupta et al. evaluated the ability of MSCs to repair Escherichia coli endotoxin- induced lung injury. They found that the overall survival rate of engrafted MSCs was significantly increased, compared with the control group. At the same time, the amount of edema and epithelial tissue infiltration were greatly reduced, when compared to the control group. Approximately 4 hours after the exposure, the direct distribution of MSCs in the air spaces resulted in a significant reduction in pro-inflammatory cytokines, such as TNF- α and MIP-2, and an increase in the anti-inflammatory cytokine IL-10 in lavage fluid and plasma. Finally, that study demonstrated that intrabronchial infusion of MSCs is able to reduce the effects of endotoxin, and to prolong survival of mice.¹² In addition, in 2009 Leblondet al. showed that intrabronchial injection of stem cells could be a promising way for the treatment of animal models of airway injury.¹⁴⁸

In another study by Wong et al. in 2007, bone marrow cells were used for the targeted treatment of naphthalene-induced airway injury. The study showed that these cells can survive for 120 days in the damaged tissue and stimulate its repair. Analysis performed on airways and alveoli also revealed the increased expression of lung epithelial proteins, Clara cell

Mesenchymal Stem Cell Therapy for Pulmonary Diseases

secretory proteins and the surfactant protein C.¹⁴⁹ In a mouse model with damaged airway, decreased and increased expression levels of TGF- β and IL-10 were found following the use of MSCs, respectively.¹⁵⁰

Recent study on mice model with chronic allergic inflammation has shown that after intravenous injection of 2×10^6 cells, bone marrow-derived mononuclear cells (BMDMC) are able to reduce airway remodeling at the site of damaged tissue. Interestingly, BMDMC therapy reduces eosinophil infiltration, expression of actin-specific smooth muscle cells, subepithelial fibrosis, and myocyte hypertrophy as well as hyperplasia. This results in reduced airway hyper responsiveness and lung mechanical parameters. Although being able to increase the expression of insulin-like growth factor, BMDMC reduces IL-5, TGF- β , platelet-derived growth factor and mRNA expression of vascular endothelial growth factor. The results indicated that cell therapy can be used in a model of chronic allergic airway inflammation as an effective method in the repair of airway epithelial cells, inhibition of inflammatory processes and airway remodeling.¹⁵¹

In the mouse model following bleomycin treatment, the administration of MSCs was able to decrease inflammatory cell infiltration significantly, reducing the inflammation.¹⁵² The application of MSCs in the C57BL/6 mouse model of acute lung injury (ALI) resulted in reduced pulmonary edema, lung neutrophil numbers, and inflammatory cytokines in BAL fluid and serum.¹³¹ In studies by Yagi, Olivera, and Sun et al. in a rat model with acute lung injury induced by endotoxin, the administration of MSCs led to an increase in survival time, and a decrease in the symptoms of lung injury, pulmonary edema, numbers of neutrophils in BAL fluid, and pro-inflammation cytokines.^{130,153,154}

In another experimental study, the effects of endotoxin in two strains of mice, BALB/c and C57BL/6, were examined. Significant improvements were found following MSC administration, including regeneration of alveolar fluid filtration, increased survival rate and reduced pro-inflammatory cytokines.⁹⁵

A potential use of MSCs to repair bleomycin-induced lung damage in rat model showed improvements associated with reduced pulmonary fibrosis, increased survival and decreased airway necrosis.¹⁵⁵ In another study, the therapeutic effects of human umbilical cord-derived MSCs were examined on a mouse model of plant toxin-induced injury;

however, the findings of the study showed a decrease in pro-inflammatory cytokines, lung injury, pulmonary edema and numbers of neutrophils in BAL and an increase in BAL fluid protein levels.¹⁵⁶

In a study by Andrade et al. in 2007, the Gelfoam sponge and rat lung cells were used for lung tissue repair. The results obtained from cell-based tissue engineering for lung regeneration showed that use of sponges after injection can produce a porous structure similar to that of native lung tissue; this can be effective in furthering the lung tissue engineering.¹⁵⁷ Lee et al. studied oleic acid-induced lung injury in ex vivo, as well as the potential role of MSCs in cell therapy. The results of that study demonstrated a reduction of endothelial dysfunction and pulmonary edema with an increase in endothelial barrier function.¹⁰⁵ Fang et al., studied the effect of human MSCs on human alveolar type II cells in cell culture in the presence of inflammatory cytokines (IL-1 β , TNF α , IFN γ). The results indicated a reduction in epithelial permeability to proteins, in turn resulting in inflammation reduction.¹⁵⁸

CONCLUSION

Since airways are severely damaged in pulmonary problems, drug therapy is not effective enough. Immunomodulatory and growth characteristics of MSCs have the great potential to treat various diseases in preclinical studies and in phase I to III clinical trials. The advantages of cell therapy over other treatments include innocuous side effects and lower costs. Hopefully, bone marrow-derived MSCs can be isolated, cultured and manipulated under ex vivo conditions, then released into the lung to prompt regeneration of damaged lung tissue. Although the use of MSCs has reduced the severity of diseases, the long term data for safety of this therapeutic method is demanded. In addition, there is a need for more information about different functional and proliferative properties of MSCs derived from bone marrow or adipose tissues of patients versus healthy subjects. To prevent transmission of prion and viral agents into the recipient's cell population, the improvement of stringent safety conditions is essential to culture MSCs. Additionally, the use of allogeneic MSCs may increase the risk of acquiring infectious diseases from the donor. Hence, it is necessary to assess all phenotypic characteristics of MSCs to facilitate preclinical studies.

However, there are potential risks in the clinical application of human MSCs. According to immunosuppressive features of the immune system in the treatment of inflammatory and immune-mediated diseases, MSCs can be considered as a great promise for future treatments in humans.

ACKNOWLEDGEMENTS

We would like to thank Mr. Eisa Tahmasbpour, Dr.Sadegh Azimzadeh and Mr.Saber Imani who gave advice and helped in writing the manuscript. We should also mention that this review has been extracted from PhD thesis of Mr. Amir Nejadmoghadam.

REFERENCES

1. Balharry D, Sexton K, BéruBé KA. An in vitro approach to assess the toxicity of inhaled tobacco smoke components: nicotine, cadmium, formaldehyde and urethane. *Toxicology* 2008; 244(1):66-76.
2. BéruBé K, et al., Characterisation of airborne particulate matter and related mechanisms of toxicity: an experimental approach. *Air pollution reviews*, 2006. 3: p. 69-109.
3. BeruBe K, Jones T, Jones C. Environmental Particles: A Breath of Fresh Air? *Infocus Magazine* 2008; (9):4.
4. Tuder RM, McGrath S, Neptune E. The pathobiological mechanisms of emphysema models: what do they have in common? *Pulm Pharmacol Ther* 2003; 16(2):67-78.
5. Sato K, Ozaki K, Mori M, Muroi K, Ozawa K. Mesenchymal stromal cells for graft-versus-host disease : basic aspects and clinical outcomes. *J Clin Exp Hematop* 2010; 50(2):79-89.
6. Snyder JC, Teisanu RM, Stripp BR. Endogenous lung stem cells and contribution to disease. *J Pathol* 2009; 217(2):254-64.
7. Lee J, Reddy R, Barsky L, Weinberg K, Driscoll B. Contribution of proliferation and DNA damage repair to alveolar epithelial type 2 cell recovery from hyperoxia. *Am J Physiol Lung Cell Mol Physiol* 2006; 290(4):L685-L694.
8. Reddy R, Buckley S, Doerken M, Barsky L, Weinberg K, Anderson KD, et al. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. *Am J Physiol Lung Cell Mol Physiol* 2004; 286(4):L658-67.
9. Coraux C, Nawrocki-Raby B, Hinnrasky J, Kileztky C, Gaillard D, Dani C, et al. Embryonic stem cells generate airway epithelial tissue. *Am J Respir Cell Mol Biol* 2005; 32(2):87-92.
10. Rippon HJ, Polak JM, Qin M, Bishop AE. Derivation of distal lung epithelial progenitors from murine embryonic stem cells using a novel three-step differentiation protocol. *Stem Cells* 2006; 24(5):1389-98.
11. Tashiro K, Inamura M, Kawabata K, Sakurai F, Yamanishi K, Hayakawa T, et al. Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. *Stem Cells* 2009; 27(8):1802-11.
12. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. *J Immunol* 2007; 179(3):1855-63.
13. Sueblinvong V, Loi R, Eisenhauer PL, Bernstein IM, Suratt BT, Spees JL, et al. Derivation of lung epithelium from human cord blood-derived mesenchymal stem cells. *Am J Respir Crit Care Med* 2008; 177(7):701-11.
14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* 2006; 8(4):315-7.
15. Salem HK, Thiemermann C. Thiemermann, Mesenchymal stromal cells: current understanding and clinical status. *Stem Cells* 2010; 28(3):585-96.
16. Martens TP, See F, Schuster MD, Sondermeijer HP, Hefti MM, Zannettino A, et al. Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium. *Nat Clin Pract Cardiovasc Med* 2006; (3 Suppl 1):S18-22.
17. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. *Blood* 2007; 110(10):3499-506.
18. Sasaki M, Abe R, Fujita Y, Ando S, Inokuma D, Shimizu H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. *J Immunol* 2008; 180(4):2581-7.
19. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. *Circulation* 2002; 105(1):93-8.
20. Zhang M, Mal N, Kiedrowski M, Chacko M, Askari AT, Popovic ZB, et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. *FASEB J* 2007; 21(12):3197-207.

Mesenchymal Stem Cell Therapy for Pulmonary Diseases

21. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* 2005; 105(4):1815-22.
22. Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase I trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. *Arch Iran Med* 2007; 10(4):459-66.
23. García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. *Dis Colon Rectum* 2005; 48(7):1416-23.
24. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 2004; 363(9419):1439-41.
25. Abdi R, Fiorina P, Adra CN, Atkinson M, Sayegh MH. Immunomodulation by mesenchymal stem cells a potential therapeutic strategy for type 1 diabetes. *Diabetes* 2008; 57(7):1759-67.
26. Augello A, Tasso R, Negrini SM, Cancedda R, Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. *Arthritis Rheum* 2007; 56(4):1175-86.
27. D'Agostino B, Sullo N, Siniscalco D, De Angelis A, Rossi F. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. *Expert Opin Biol Ther* 2010; 10(5):681-7.
28. Breuer R, Zajicek G, Christensen TG, Lucey EC, Snider GL. Cell kinetics of normal adult hamster bronchial epithelium in the steady state. *Am J Respir Cell Mol Biol* 1990; 2(1):51-8.
29. Rock JR, Randell SH, Hogan BL. Hogan, Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. *Dis Model Mech* 2010; 3(9-10):545-56.
30. Zhang YV, Cheong J, Ciapurin N, McDermitt DJ, Tumber T. Distinct self-renewal and differentiation phases in the niche of infrequently dividing hair follicle stem cells. *Cell Stem Cell* 2009; 5(3):267-78.
31. Erjefält JS, Persson CG. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. *Thorax* 1997; 52(11):1010-2.
32. Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. *Am J Respir Cell Mol Biol* 2001; 24(6):671-81.
33. Shimizu T, Nishihara M, Kawaguchi S, Sakakura Y. Expression of phenotypic markers during regeneration of rat tracheal epithelium following mechanical injury. *Am J Respir Cell Mol Biol* 1994; 11(1):85-94.
34. Chary P, Mitchell CE, and Kelly G. Chemical carcinogen-induced damage to the c-neu and c-myc protooncogenes in rat lung epithelial cells: possible mechanisms for differential repair in transcriptionally active genes. *Cancer Lett*, 1991. 58(1-2): p 57-63.
35. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. *Am J Physiol Lung Cell Mol Physiol* 2010; 298(6):L715-31.
36. Geiser T. Mechanisms of alveolar epithelial repair in acute lung injury--a translational approach. *Swiss Med Wkly* 2003; 133(43-44):586-90.
37. Bergeron C, Tulic MK, Hamid Q. Tools used to measure airway remodelling in research. *Eur Respir J* 2007; 29(3):596-604.
38. Busse W, Elias J, Sheppard D, Banks-Schlegel S. Airway remodeling and repair. *Am J Respir Crit Care Med* 1999; 160(3):1035-42.
39. Puchelle E, Zahm JM, Tournier JM, Coraux C. Airway epithelial repair, regeneration, and remodeling after injury in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2006; 3(8):726-33.
40. Postma DS, Timens W. Timens, Remodeling in asthma and chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2006; 3(5):434-9.
41. Redington AE, Madden J, Frew AJ, Djukanovic R, Roche WR, Holgate ST, et al. Transforming growth factor-beta 1 in asthma. Measurement in bronchoalveolar lavage fluid. *Am J Respir Crit Care Med* 1997; 156(2 Pt 1):642-7.
42. Aubert JD, Dalal BI, Bai TR, Roberts CR, Hayashi S, Hogg JC. Transforming growth factor beta 1 gene expression in human airways. *Thorax* 1994; 49(3):225-32.
43. El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, et al. Transforming growth factor beta (TGF- β) and obliterative bronchiolitis following pulmonary transplantation. *J Heart Lung Transplant* 1999; 18(9):828-37.
44. Königshoff M, Kneidinger N, Eickelberg O. TGF-beta signaling in COPD: deciphering genetic and cellular susceptibilities for future therapeutic regimen. *Swiss Med Wkly* 2009; 139(39-40):554-63.

45. Churg A, Wang RD, Tai H, Wang X, Xie C, Dai J, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor- α release. *Am J Respir Crit Care Med* 2003; 167(8):1083-9.
46. Elias JA, Kang MJ, Crothers K, Homer R, Lee CG. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice. *Proc Am Thorac Soc* 2006; 3(6):494-8.
47. Srivastava PK, Dastidar SG, Ray A. Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy. *Expert Opin Investig Drugs* 2007; 16(7):1069-78.
48. Rawlins EL, Okubo T, Que J, Xue Y, Clark C, Luo X, et al. Epithelial stem/progenitor cells in lung postnatal growth, maintenance, and repair. *Cold Spring Harb Symp Quant Biol* 2008; 73:291-5.
49. Burgess JK. The role of the extracellular matrix and specific growth factors in the regulation of inflammation and remodelling in asthma. *Pharmacol Ther* 2009; 122(1):19-29.
50. Holm AM, Riise GC, Brinch L, Bjørtuft O, Iversen M, Simonsen S, et al. Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: unresolved questions. *Transplantation* 2013; 96(4):e21-2.
51. Tzortzaki EG, Siafakas NM. A hypothesis for the initiation of COPD. *Eur Respir J* 2009; 34(2):310-5.
52. Williams KM, Chien JW, Gladwin MT, Pavletic SZ. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. *JAMA* 2009; 302(3):306-14.
53. Hong KU, Reynolds SD, Giangreco A, Hurley CM, Stripp BR. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. *Am J Respir Cell Mol Biol* 2001; 24(6):671-81.
54. Evans MJ, Shami SG, Cabral-Anderson LJ, Dekker NP. Role of nonciliated cells in renewal of the bronchial epithelium of rats exposed to NO₂. *Am J Pathol* 1986; 123(1):126-33.
55. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al., Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. *Proc Natl Acad Sci U S A* 2003; 100(14):8407-11.
56. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. Cell number and cell characteristics of the normal human lung. *Am Rev Respir Dis* 1982; 126(2):332-337.
57. Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and-independent pathways. *J Biol Chem* 2002; 277(38):35466-74.
58. Louahed J, Toda M, Jen J, Hamid Q, Renauld JC, Levitt RC, et al. Interleukin-9 upregulates mucus expression in the airways. *Am J Respir Cell Mol Biol* 2000; 22(6):649-56.
59. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J Clin Invest* 1999; 103(6):779-88.
60. Minguell JJ, Conget P, Erices A. Biology and clinical utilization of mesenchymal progenitor cells. *Braz J Med Biol Res* 2000; 33(8):881-7.
61. Minguell JJ, Erices A, Conget P. Mesenchymal stem cells. *Exp Biol Med (Maywood)* 2001; 226(6):507-20.
62. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem cells* 2001; 19(3):180-92.
63. Fridenshtein Ala, Luriia EA. [Cellular basis of the hematopoietic microenvironment]. *Ter Arkh* 1980; 52(9):67-71.
64. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. *Nature* 2002; 418(6893):41-9.
65. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *science* 1999; 284(5411):143-7.
66. da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. *Stem Cells* 2008; 26(9):2287-99.
67. Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, et al. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. *Haematologica* 2005; 90(4):516-25.
68. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T, et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. *Blood* 2007; 109(1):228-34.
69. Sato T, Hidaka K, Iwanaga A, Ito M, Asano M, Nakabeppu Y, et al. Impairment of cardiomyogenesis in

Mesenchymal Stem Cell Therapy for Pulmonary Diseases

- embryonic stem cells lacking scaffold protein JSAP1. *Biochem Biophys Res Commun* 2005; 338(2):1152-7.
70. Ghazanfari, S., et al. Analysis of alterations in morphologic characteristics of mesenchymal stem cells by mechanical stimulation during differentiation into smooth muscle cells. *Yakhteh Medical Journal* 2010; 12(1):73-80.
 71. Bayati V, Sadeghi Y, Shokrgozar MA, Haghighipour N, Azadmanesh K, Amanzadeh A, et al. The evaluation of cyclic uniaxial strain on myogenic differentiation of adipose-derived stem cells. *Tissue Cell* 2011; 43(6):359-66.
 72. Haghighipour N, Heidarian S, Shokrgozar MA, Amirizadeh N. Differential effects of cyclic uniaxial stretch on human mesenchymal stem cell into skeletal muscle cell. *Cell Biol Int* 2012; 36(7):669-75.
 73. Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. *J Intern Med* 2007; 262(5):509-25.
 74. Miura M¹, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. *Stem Cells* 2006; 24(4):1095-103.
 75. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone* 2003; 33(6):919-26.
 76. Löbel M, Bauer S, Meisel C, Eisenreich A, Kudernatsch R, Tank J, et al. CCN1: a novel inflammation-regulated biphasic immune cell migration modulator. *Cell Mol Life Sci* 2012; 69(18):3101-13.
 77. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. *Nat Immunol* 2005; 6(12):1182-90.
 78. Salcedo R, Oppenheim JJ. Oppenheim, Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses. *Microcirculation* 2003; 10(3-4):359-70.
 79. Spring H, Schüler T, Arnold B, Hämmerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. *Proc Natl Acad Sci U S A* 2005; 102(50):18111-6.
 80. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. *Blood* 2005; 106(2):419-27.
 81. Ruster B, Göttig S, Ludwig RJ, Bistrrian R, Müller S, Seifried E, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. *Blood* 2006; 108(12):3938-44.
 82. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? *Blood* 2005; 106(6):1901-10.
 83. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. *Nature* 2001; 414(6859):98-104.
 84. Lapidot T. Mechanism of human stem cell migration and repopulation of NOD/SCID and B2mnull NOD/SCID mice. The role of SDF-1/CXCR4 interactions. *Ann N Y Acad Sci* 2001; 938:83-95.
 85. Chapel A, Bertho JM, Bensidhoum M, Fouillard L, Young RG, Frick J, et al. Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. *J Gene Med* 2003; 5(12):1028-38.
 86. Conget PA, Minguell JJ. Minguell, Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. *J Cell Physiol* 1999; 181(1):67-73.
 87. Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. *Leukemia* 2007; 21(8):1733-8.
 88. Shi M, Li J, Liao L, Chen B, Li B, Chen L. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. *Haematologica* 2007; 92(7):897-904.
 89. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide novel opportunities in (stem) cell-free therapy. *Front Physiol* 2012; 3:359.
 90. Hogan NM, Joyce MR, Murphy JM, Barry FP, O'Brien T, Kerin MJ, et al. Impact of mesenchymal stem cell secreted PAI-1 on colon cancer cell migration and proliferation. *Biochem Biophys Res Commun* 2013; 435(4):574-9.
 91. von Andrian UH. A massage for the journey: keeping leukocytes soft and silent. *Proc Natl Acad Sci U S A* 1997; 94(10):4825-7.
 92. Von Lüttichau I, Notohamiprodjo M, Wechselberger A, Peters C, Henger A, Seliger C, et al. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. *Stem Cells Dev* 2005; 14(3):329-36.
 93. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. *Cytokine Growth Factor Rev* 2009; 20(5-6):419-27.
 94. Han KH, Ro H, Hong JH, Lee EM, Cho B, Yeom HJ, et

- al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. *Transpl Immunol* 2011; 25(1):7-15.
95. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. *Nat Med* 2009; 15(1):42-9.
96. Gebler A, Zabel O, Seliger B. The immunomodulatory capacity of mesenchymal stem cells. *Trends Mol Med* 2012; 18(2):128-34.
97. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. *J Cell Physiol* 1998; 176(1):57-66.
98. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. *J Exp Med* 1988; 167(2):332-44.
99. Splawski JB, McAnally LM, Lipsky PE. IL-2 dependence of the promotion of human B cell differentiation by IL-6 (BSF-2). *J Immunol* 1990; 144(2):562-9.
100. Choi YS, Jeong JA, Lim DS. Mesenchymal stem cell-mediated immature dendritic cells induce regulatory T cell-based immunosuppressive effect. *Immunol Invest* 2012; 41(2):214-29.
101. Lu L, Wang DD, Li X, Zeng XF, Sun LY. [Mechanism of umbilical cord mesenchymal stem cells in the up-regulation of regulatory T cells by transforming growth factor beta1 in systemic lupus erythematosus]. *Zhonghua Yi Xue Za Zhi* 2013; 93(13):980-3.
102. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. *Stem Cells* 2008; 26(1):212-22.
103. Wang L, Li Y, Chen J, Gautam SC, Zhang Z, Lu M, et al. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. *Exp Hematol* 2002; 30(7):831-6.
104. Wang L, Li Y, Chen X, Chen J, Gautam SC, Xu Y, et al. MCP-1, MIP-1, IL-8 and ischemic cerebral tissue enhance human bone marrow stromal cell migration in interface culture. *Hematology* 2002; 7(2):113-7.
105. Lee JW, Fang X, Gupta N, Serikov V, Matthay MA. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. *Proc Natl Acad Sci U S A* 2009; 106(38):16357-62.
106. Bassi, E.J., C.A. Aita, and N.O. Camara, Immune regulatory properties of multipotent mesenchymal stromal cells: Where do we stand? *World J Stem Cells*, 2011. 3(1): p. 1-8.
107. Mielcarek, M., et al., Mesenchymal stromal cells fail to prevent acute graft-versus-host disease and graft rejection after dog leukocyte antigen-haploidentical bone marrow transplantation. *Biol Blood Marrow Transplant*, 2011. 17(2): p. 214-25.
108. Deans, R.J. and A.B. Moseley, Mesenchymal stem cells: biology and potential clinical uses. *Exp Hematol*, 2000. 28(8): p. 875-84.
109. Morandi, F., et al., Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. *Stem Cells*, 2008. 26(5): p. 1275-87.
110. DelaRosa O, Lombardo E. Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential. *Mediators Inflamm* 2010; 2010:865601.
111. Lei J, Wang Z, Hui D, Yu W, Zhou D, Xia W, et al. Ligation of TLR2 and TLR4 on murine bone marrow-derived mesenchymal stem cells triggers differential effects on their immunosuppressive activity. *Cell Immunol* 2011; 271(1):147-56.
112. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling. *Stem cells* 2008; 26(1):279-89.
113. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Köppel A, et al. Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2, 3-dioxygenase-1 via Interferon- β and Protein Kinase R. *Stem Cells* 2009; 27(4):909-919.
114. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. *Blood* 2006; 107(1):367-72.
115. Shi M, Liu ZW, Wang FS. Immunomodulatory properties and therapeutic application of mesenchymal

Mesenchymal Stem Cell Therapy for Pulmonary Diseases

- stem cells. *Clin Exp Immunol* 2011; 164(1):1-8.
116. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol* 2011; 6:457-78.
117. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* 2006; 107(4):1484-90.
118. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. *Stem Cells Dev* 2004; 13(3):263-71.
119. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood* 2003; 101(8):2999-3001.
120. Duffy MM, Ritter T, Ceredig R, Griffin MD. Mesenchymal stem cell effects on T-cell effector pathways. *Stem Cell Res Ther* 2011; 2(4):34.
121. Luz-Crawford P, Kurte M, Bravo-Alegría J, Contreras R, Nova-Lamperti E, Tejedor G, et al. Mesenchymal stem cells generate a CD4+CD25+Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. *Stem Cell Res Ther* 2013; 4(3):65.
122. Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringdén O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp Hematol* 2003; 31(10):890-6.
123. Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. *Transplantation* 2007; 84(2):231-7.
124. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells* 2006; 24(2):386-98.
125. Jacobs SA, Plessers J, Pinxteren J, Roobrouck VD, Verfaillie CM, Van Gool SW. Mutual interaction between Human Multipotent Adult Progenitor Cells and NK cells. *Cell transplant* 2014; 23(9):1099-110.
126. Mao F, Xu WR, Qian H, Zhu W, Yan YM, Shao QX, et al. Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. *Inflamm Res* 2010; 59(3):219-25.
127. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. *Cell Immunol* 2008; 251(2):131-6.
128. Nauta AJ, Krusselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. *J Immunol* 2006; 177(4):2080-7.
129. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 2010; 28(12):2229-38.
130. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, et al. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. *J Transl Med* 2011; 9:118.
131. Xu J, Woods CR, Mora AL, Joodi R, Brigham KL, Iyer S, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. *Am J Physiol Lung Cell Mol Physiol* 2007; 293(1):L131-41.
132. Rock JR, Onaitis MW, Rawlins EL, Lu Y, Clark CP, Xue Y, et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. *Proc Natl Acad Sci U S A* 2009; 106(31):12771-5.
133. Loi R, Beckett T, Goncz KK, Suratt BT, Weiss DJ. Limited restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow-derived cells. *Am J Respir Crit Care Med* 2006; 173(2):171-9.
134. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. *Cell* 2001; 105(3):369-77.
135. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. *Development* 2001; 128(24):5181-8.
136. Loebinger MR, Janes SM. Stem cells for lung disease. *Chest* 2007; 132(1):279-85.
137. Marshall HE 3rd, Keenan KP, McDowell EM. The stathmokinetic and morphological response of the hamster respiratory epithelium to intralaryngeal instillations of saline and ferric oxide in saline. *Fundam Appl Toxicol* 1987; 9(4):705-14.
138. Kauffman SL. Cell proliferation in the mammalian lung. *Int Rev Exp Pathol* 1980; 22:131-91.
139. Breuer R, Christensen TG, Wax Y, Bolbochan G, Lucey EC, Stone PJ, et al. Relationship of secretory granule

- content and proliferative intensity in the secretory compartment of the hamster bronchial epithelium. *Am J Respir Cell Mol Biol* 1993; 8(5):480-5.
140. Weiss DJ, Casaburi R, Flannery R, LeRoux-Williams M, Tashkin DP. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. *Chest* 2013; 143(6):1590-8.
141. Ra JC, Shin IS, Kim SH, Kang SK, Kang BC, Lee HY, et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. *Stem Cells Dev* 2011; 20(8):1297-308.
142. Angelini DJ, Dorsey RM, Willis KL, Hong C, Moyer RA, Oyler J, et al. Chemical warfare agent and biological toxin-induced pulmonary toxicity: could stem cells provide potential therapies? *Inhal Toxicol* 2013; 25(1):37-62.
143. Liang, W., H. Xia, Y. Wang, Allogeneic Mesenchymal Stem Cells Injections for the Treatment of Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cells Transplant. *J Cancer Sci Ther* 2012:4-7.
144. Serikov VB, Popov B, Mikhailov VM, Gupta N, Matthay MA. Evidence of temporary airway epithelial repopulation and rare clonal formation by BM-derived cells following naphthalene injury in mice. *Anat Rec* 2007; 290(9):1033-45.
145. Gomperts BN, Belperio JA, Fishbein MC, Keane MP, Burdick MD, Strieter RM. Keratinocyte growth factor improves repair in the injured tracheal epithelium. *Am J Respir Cell Mol Biol* 2007; 37(1):48-56.
146. Tzouveleakis A, Koliakos G, Ntoliou P, Baira I, Bouros E, Oikonomou A, et al. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. *J Transl Med* 2011; 9:182.
147. Nichols JE, Niles JA, Cortiella J. Production and utilization of acellular lung scaffolds in tissue engineering. *J Cell Biochem* 2012; 113(7):2185-92.
148. Leblond AL, Naud P, Forest V, Gourden C, Sagan C, Romefort B, et al. Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. *Hum Gene Ther* 2009; 20(11):1329-43.
149. Wong AP, Dutly AE, Sacher A, Lee H, Hwang DM, Liu M, et al. Targeted cell replacement with bone marrow cells for airway epithelial regeneration. *Am J Physiol Lung Cell Mol Physiol* 2007; 293(3):L740-52.
150. Grove DA, Xu J, Joodi R, Torres-Gonzales E, Neujahr D, Mora AL, et al. Attenuation of early airway obstruction by mesenchymal stem cells in a murine model of heterotopic tracheal transplantation. *J Heart Lung Transplant* 2011; 30(3):341-50.
151. Abreu SC, Antunes MA, Maron-Gutierrez T, Cruz FF, Carmo LG, Ornellas DS, et al. Effects of bone marrow-derived mononuclear cells on airway and lung parenchyma remodeling in a murine model of chronic allergic inflammation. *Respir Physiol Neurobiol* 2011; 175(1):153-63.
152. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. *Proc Natl Acad Sci U S A* 2007; 104(26):11002-7.
153. Liang ZX, Sun JP, Wang P, Tian Q, Yang Z, Chen LA. Bone marrow-derived mesenchymal stem cells protect rats from endotoxin-induced acute lung injury. *Chin Med J (Engl)* 2011; 124(17):2715-22.
154. Yagi H, Soto-Gutierrez A, Kitagawa Y, Tilles AW, Tompkins RG, Yarmush ML. Bone marrow mesenchymal stromal cells attenuate organ injury induced by LPS and burn. *Cell Transplant* 2010; 19(6):823-30.
155. Zhao F, Zang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, Qi HW. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. *Transplant Proc.* 2008 Jun;40(5):1700-5
156. Li J, Li D, Liu X, Tang S, Wei F. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. *J Inflamm (Lond)* 2012; 9(1):33.
157. Andrade CF, Wong AP, Waddell TK, Keshavjee S, Liu M. Cell-based tissue engineering for lung regeneration. *Am J Physiol Lung Cell Mol Physiol* 2007; 292(2):L510-8.
158. Fang X, Neyrinck AP, Matthay MA, Lee JW. Allogeneic human mesenchymal stem cells restore epithelial protein permeability in cultured human alveolar type II cells by secretion of angiopoietin-1. *J Biol Chem* 2010; 285(34):26211-22.